key: cord-0901351-58cj3tqh
authors: Ricciardiello, Luigi; Ferrari, Clarissa; Cameletti, Michela; Gaiani, Federica; Buttitta, Francesco; Bazzoli, Franco; Luigi de’Angelis, Gian; Malesci, Alberto; Laghi, Luigi
title: Impact of SARS-CoV-2 pandemic on colorectal cancer screening delay: effect on stage shift and increased mortality
date: 2020-09-06
journal: Clin Gastroenterol Hepatol
DOI: 10.1016/j.cgh.2020.09.008
sha: 038513e6b25a0613330eee4ab9bf4901f6a66967
doc_id: 901351
cord_uid: 58cj3tqh

Background and Aims The SARS-CoV-2 pandemic had a sudden, dramatic impact on healthcare. In Italy, since the beginning of the pandemic, colorectal cancer (CRC) screening programs have been forcefully suspended. We aimed to evaluate whether screening procedure delays can affect the outcomes of CRC screening. Methods We built a procedural model considering delays in the time to colonoscopy and estimating the effect on mortality due to up-stage migration of patients. The number of expected CRC cases was computed by using the data of the Italian screened population. Estimates of the effects of delay to colonoscopy on CRC stage, and of stage on mortality were assessed by a meta-analytic approach. Results With a delay of 0-3 months, 74% of CRC is expected to be stage I-II, while with a delay of 4-6 months there would be a 2%-increase for stage I-II and a concomitant decrease for stage III-IV (p=0.068). Compared to baseline (0-3-months), moderate (7-12-months) and long (>12-months) delays would lead to a significant increase in advanced CRC (from 26% to 29% and 33%, respectively; p=0.008 and p<0.001, respectively). We estimated a significant increase in the total number of deaths (+12.0%) when moving from a 0-3-months to a >12-month delay (p=0.005), and a significant change in mortality distribution by stage when comparing the baseline with the >12-months (p<0.001). Conclusions Screening delays beyond 4-6 months would significantly increase advanced CRC cases, and also mortality if lasting beyond 12 months. Our data highlight the need to reorganize efforts against high-impact diseases such as CRC, considering possible future waves of SARS-CoV-2 or other pandemics.

The SARS-CoV-2 pandemic era affected the healthcare organizations/systems in every country, irrespective of differences in political governance, economic resources, or type of health care reimbursement. Mounting pressure for emergency admissions and intensive care support resulted in a surge of access to hospitals, prompting the downscaling of almost all clinical activities to face the unexpected spread of the disease and its lifethreatening complications 1 . In Europe, the enormous diversion of medical resources towards SARS-CoV-2-dedicated wards dominated the clinical scenarios 2 , with almost all planned public healthcare activities, including cancer screening, being suspended. As of now, in Italy it is difficult to discern the excess of deaths registered in the early spring according to their relationship with SARS-CoV-2 or with high-impact illnesses that remained unrecognized and possibly untreated.

Regarding cancer incidence and mortality, colorectal cancer (CRC) represents a major burden worldwide 3 , but can be counteracted by screening strategies. Currently, in the U.S., the implementation of an opportunistic approach by screening colonoscopy has contributed to a gradual reduction of CRC incidence 4 , while European countries mostly rely on programmatic screening by biannual faecal immunochemical test (FIT) 5 . The adoption of FIT reduces CRC mortality mainly through the detection of early stage tumors, which leads to a down-staging process 6 . To meet their benchmark reduction of CRC burden, FIT-based screening programs rely on a multilayer system involving public health authorities, kit distribution facilities, FIT measuring labs, and ultimately, hospitals/centers where FIT+ subjects undergo colonoscopy. Since the beginning of the pandemic, this entire system has been put on hold. On March 8 and 11, 2020, the Italian government issued decrees that greatly reduced gathering and interpersonal contacts, which added to the above mentioned pressures on the healthcare system, further restraining cancer screening 7 . Heterogeneous decisions involved the management of tests at the first (by J o u r n a l P r e -p r o o f interrupting active calls), as well as at the second level (by placing on hold endoscopic examination for FIT+ subjects), with some coordinating units opting to shut down both levels.

Recent data highlighted the detrimental effects on mortality of delaying diagnosis in symptomatic patients with CRC in the UK 8 , due to SARS-Cov2 pandemic. However, screening delays might have even more dramatic effects than delayed diagnosis, once the downstaging effect is reversed by the delays. Accordingly, we sought to assess the impact of the pandemic on programmatic CRC screening, building a meta-analytic procedural model which considers time-delays in the access to colonoscopy and estimates the effect on mortality due to the consequent up-stage migration of patients over time.

J o u r n a l P r e -p r o o f

We followed a stepwise rationale in building the procedural model, based upon the following relationships: i) the stage at the time of diagnosis affects CRC mortality; ii) the stage at diagnosis largely depends on an early detection of malignant and pre-malignant lesions, which is strictly related to, and improved by, timeliness of screening programs.

Considering the delay in the screening procedures imposed by SARS-CoV-2 pandemic, we explored the relationships "delay-stage" and "stage-mortality" (referred to as "DS" and "SM", respectively) under the constraints of different delay spans, with the aim of providing an estimate of the effect of pandemic on CRC mortality. The evaluation of the two relationships "DS" and "SM" was based on literature evidence, obtained by performing two separate meta-analyses.

Eventually, the chain effect of the screening delay due to Sars-Cov2 pandemic was quantified in terms of the number of deaths expected to occur in a general, asymptomatic population which would have otherwise adhered to and undergone programmatic screening (see Figure 1 ).

To pursue the main aim of the study, we conducted a systematic literature search through the Pubmed and Scopus databases, in a two-step process. For the first literature review on "DS", we built a pipeline for papers providing the distribution of CRC stage by delay strata (outcome of interest: percentage/proportion of CRC by stage and delay), identified by the time for access to colonoscopy after a positive FIT. For the second step, concerning "SM", the outcome of interest was the 5-year (age-adjusted) survival rates stratified by stage of CRC patients. Specifically, we applied the following search strategies: J o u r n a l P r e -p r o o f assessed by reading the full-texts. For both the "DS" and "MS" meta-analyses, two of the authors (LR-LL) carried out the search independently. Any disagreements were discussed and resolved with the involvement of a third researcher. All the screened articles and corresponding decisions were recorded in an Excel spreadsheet. For the detailed search sequences see Figure S1 and S2.

From the "DS" search we selected 8 papers (see Figure S1 ) [10] [11] [12] [13] [14] [15] [16] [17] and extracted the following variables (Table S1 ): year of publication, country, delay (in months), stage, number of CRC cases by stage and delay and total number of CRC cases.

Because delay categories were not homogeneous across the included studies (with some papers using monthly delay intervals and others adopting longer time lags), we adopted 4 categories for delay times (i.e., 0-3 months, 4-6 months, 7-12 months and >12 J o u r n a l P r e -p r o o f months) as these intervals covered most waiting times across the selected studies. The studies also differed as to the reported stage categories, some using TNM classification (i.e., stage I, II, III, IV) and others reporting pooled stages (i.e., "advanced" for stage III and IV). To allow comprehensive data capture for the analysis, we adopted the early vs advanced stage classification, by aggregating data of stages I and II (early stage) and data of stages III and IV (advanced stage).

For the "SM" search, 10 papers were selected (see Figure S2 ) [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] , and the following variables were extracted (see Table S2 ): year of publication, country, stage, 5-years agestandardized survival rate by stage and total number of CRC cases. Also, for this analysis we adopted the stage classification of early vs advanced tumors.

The Newcastle Ottawa Scale (NOS) for cohort studies (score range 0-9) was used to assess the quality of the included studies 28 . Studies with score greater than 5 were considered of high quality (see Table S3 ).

We used the data gathered from the "DS" literature search to calculate the meta-analytic and its metafor package 29 . The level of statistical significance was set at p < 0.05.

The pooled estimates of stage distribution of screen detected CRC according to pre-SARS-CoV-2 era data are reported in Figure S3 . With a brief, already present delay of 0-3 months, 74% of the CRC is expected to be stage I-II, and a delay of 4-6 months will lead to a non-significant increase in stage I-II prevalence (from 74% to 76%), and to a concomitant decrease of stage III-IV (from 26% to 24%) prevalence (p=0.068) ( Table 1) .

Conversely, compared to the reference 0-3 months, our analysis estimated a significant increase in advanced cancers detected at screening for a moderate 7-12-month delay (from 26% to 29%; p=0.008), which progressively worsened after a 12-month delay (up to 33%; p<0.001). These results indicate a shift in the distribution of screen-detected CRC by stage at diagnosis, marked by a significant rise in the proportion of advanced cases with a delay beyond 6 months.

Next, we evaluated the survival of subjects supposed to undergo programmatic screening according to pooled survival rates (at 5 years) estimated by "SM" meta-analysis ( Figure 4S and Table 2 ). This analysis revealed a survival rate of 0.85 (95%CI: 0.81-0.88) for stage I-II diagnoses, and 0.39 (95%CI: 0.33-0.44) for stage III-IV..

To quantify the expected number of deaths resulting from the "funnel" effect on the otherwise ongoing screening, we focused on the Italian population, and determined the (Table S4 ). The number of CRC cases was used to quantify the expected number of deaths.

By applying the proportions of the estimates in the pre-SARS-CoV-2 era (reported in Table   1 ) to 3,184 incident CRC cases, we derived the expected number of cases, stratified by stage occurring in the scenario overrun by delays. These estimates, combined with the mortality rates (derived from Table 2 ), allowed calculating the expected number of deaths at 5-years for each delay-stage scenario, which are reported in Table 3 . A significant increase in the total number of deaths (+12%) was estimated when moving from a 0-3 month (reference delay) to a >12-month delay (p=0.005). We did not detect significant changes in the number of deaths with respect to baseline for delays <12 months.

Furthermore, we computed the relative percentage changes in expected deaths by stage (Table 3) . At 4-6 months, we observed 2.8% increase in the mortality for stage I-II cancers, and 7.7% decrease for stage III-IV. These changes correspond to a 2% shift in the early vs advanced stage distribution reported in Table 1 . However, mortality by stage at 4-6 as well as at 7-12 months was not significantly different from the baseline scenario (p=0.294 and p=0.139, respectively). Conversely, we observed a significant change by comparing the baseline with the >12-month mortality distribution by stage (p<0.001).

J o u r n a l P r e -p r o o f

We estimated the effects of the lockdown due to the SARS-CoV-2 pandemic on programmatic colorectal cancer screening, and their impact on disease burden by a rigorous, meta-analytical model. . Our analysis indicates that delays up to 4-6 months do not significantly reduce the performance of screening, while a lockdown sustained for longer time-frames would negatively affect mortality rates. This should be ascribed to the progressive shift of screen-detected cancers towards advanced stages, a change becoming significant in the 7-12-month delay interval. In usual circumstances, only a minor fraction of FIT positive subjects would receive a delayed colonoscopy (ranging from 0.8% to 6.2%, after 6 months) 11, 17 . The effects of the pandemic may modify previously reassuring estimates in a time-dependent way, as a fraction of neoplastic lesions detected by FIT may progress from month 6 to 12 17 , increasing overall colorectal cancer deaths by more than one tenth, including an excess of one out of four advanced cases.

At 6 months, the model envisioned a non-significant, transitory additional 2% diagnostic rate of stage I-II tumors, coupled with a 2% reduction in stage III-IV ones, in keeping with data used in the "DS" meta-analysis 11, 17 , in which some studies reported reduced risks of detecting advanced stages. We do not have a direct explanation for these changes, that might be interpreted as "waiting time paradox" at the first delay interval. Of interest, diagnostic delays up to 6 months have been associated with earlier stages across symptomatic patients, in keeping with a similar paradox 31,32 that needs to be investigated in further research. Our analysis indicates that the backlog sustained beyond 6 months would unequivocally ensue in a significant excess of advanced stages detected through screening, and thus in up-rather than down-staging. Such an increase of advanced stages in the 7-12-month interval of delay, although not affecting the mortality rate at 5 years, will nevertheless increase disease burden, human and economic costs.

The results presented in this study were obtained by applying the meta-analytic estimates to the Italian screened population. However, the figures obtained from the "DS"-"MS" meta-analyses could be easily applied to other CRC target screening populations.

Moreover, the proposed procedural model could be recommended also for other cancers amenable to screening programs.

The main limitation of our study, which is based on meta-analytic results rather than on direct data, is the small number of primary studies included in the two meta-analyses.

Although this could affect the robustness of the findings, the adopted random-effect metaanalysis models mitigate this drawback. Importantly, our meta-analytic approach represents a strength, as it generated a prompt quantification of the results of the delay on the outcome of CRC screening that may help planning timely public health decisions.

In addition, it is worth noting that our quantification on the Italian screening population should be considered as an illustrative example of the consequence of the screening delay on CRC stage shift and mortality. Once the observed data on CRC stage and mortality is gathered after the pandemic, it will be very informative to make a comparison with our results.

Finally, from the studies included in our metanalysis, we could not unequivocally extrapolate the reasons explaining for the delays in colonoscopy after a positive FIT test.

Only Flugelman et al. 12 reviewing the data from the 304 patients (17% of the cohort) who deferred follow-up beyond 1 year, found that the main reason (in 90% of them) was the lack of adherence to positive fecal test follow-up guidelines.

The appearance of an urgent, unexpected and unmet medical need is bringing a collateral, un-estimated impact on fields subject to a constant improvement in the last decades. In the US, the Centers for Medicare & Medicaid Services issued guidance that colonoscopies for colorectal cancer screening had to be delayed from mid-March, raising the concern that delay of CRC screening for 23 million US adults would lead to a delayed diagnosis and increased mortality 33 . The need to resume key healthcare activities, including oncological screening programs, is not counterbalanced by strategic plans considering the backlog. Indeed, in Italy, these stops will break a chain of about 6.000.000

yearly invitations for FIT, so that just a 2-month delay accounts for the lack of approximately 1.000.000 notices, with a parallel decrease in the 50% rate of pick-up, and a consequent loss of the estimated 5% positive tests among responders. Unfortunately,

given the highly unlikely scenario of full resumption of screening activities in the short term , we could envision that such backlog would lead to a long-lasting carryover, with significant negative consequences on the epidemiology of the disease.

The incoming challenge is to look forward to the demand for medical activities in the post-SARS-CoV-2, not only with respect to acute disorders, but also for chronic and multifactorial diseases, such as cancer, for which preventive attitudes and screening programs play a major role in reducing disease burden and mortality. In this perspective, designing new, proactive plans requires the proper evaluation of the scenarios ahead, to counteract stops and delays imposed by the SARS-Cov2 pandemic. This is of outmost importance in the view of possible, future waves of SARS-CoV-2 infections 34 .

In conclusion, our study shows that CRC screening delays beyond 6 months would result in a significantly higher number of more advanced CRC cases; correspondingly, delays beyond 12 months would increase disease mortality. Thus, we believe that alternative strategies should envision future lockdowns and social distancing, re-thinking the paths of 

The SARS-CoV-2 pandemic has had a sudden impact on colon cancer screening programs. We demonstrate that screening delays beyond 6 months would increase disease mortality rates through the progressive shift to more advanced stages. In the light of possible future waves of SARS-CoV-2 or other pandemics, our findings warn against screening delays above 12 months to restrain the negative impact on disease mortality. J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f Figure S1 . Flowchart for the "stage-delay" meta-analysis. Records Full-text articles excluded (n=9) with reasons: -no delay data; -no stage percentages*. * One study was excluded because it provides the percentages by stage only in graphical form. A data request to the authors was made by email, but no reply was obtained.

(meta-analysis) (n = 8)

Records identified through database searching SCOPUS (n = 343) Figure S2 . Flowchart for the "delay-mortality" meta-analysis. Records J o u r n a l P r e -p r o o f Table S1 . Papers included in the "delay-stage" meta-analysis (n CRC represents the number of CRC cases for each delay and stage; n total CRC is the total number of CRC cases).

Year J o u r n a l P r e -p r o o f 

Novel Coronavirus and Old Lessons -Preparing the Health System for the Pandemic

2019-ncov's epidemic in middle province of northern Italy: Impact, logistic & strategy in the first line hospital

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Colonoscopy reduces colorectal cancer incidence and mortality in patients with non-malignant findings: A meta-analysis

Performance of colorectal cancer screening in the European Union Member States: Data from the second European screening report

Trends of colorectal cancer incidence and mortality rates from 2003 to 2014 in Italy

COVID-19 in Italy: momentous decisions and many uncertainties

Quantifying and mitigating the impact of the COVID-19 pandemic on outcomes in colorectal cancer

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

Association between time to colonoscopy after a positive guaiac fecal test result and risk of colorectal cancer and advanced stage disease at diagnosis

Association between time to colonoscopy after a positive fecal test result and risk of colorectal Cancer and Cancer stage at Diagnosis

Delayed Colonoscopy Following a Positive Fecal Test Result and Cancer Mortality

Time to colonoscopy, cancer probability, and precursor lesions in the danish colorectal cancer screening program

Association of time to colonoscopy after a positive fecal test result and fecal hemoglobin concentration with risk of advanced colorectal neoplasia

Time to Colonoscopy and Risk of Colorectal Cancer in Patients With Positive Results From Fecal Immunochemical Tests

Effect of time to diagnostic testing for breast, cervical, and colorectal cancer screening abnormalities on screening efficacy: A modeling study

Colonoscopy later than 270 days in a fecal immunochemical test-based population screening program is associated with higher prevalence of colorectal cancer

An overview of 25 years of incidence, treatment and outcome of colorectal cancer patients

Incidence and survival of adult cancer patients in Taiwan

Revised TN categorization for colon cancer based on national survival outcomes data

Subsite-and stage-specific colorectal cancer trends in Estonia prior to implementation of screening

Prognostic Effect of Tumor Sidedness in Colorectal Cancer: A SEER-Based Analysis

Disease presentation, treatment and survival for Italian colorectal cancer patients: A EUROCARE high resolution study

Oncological treatment and outcome of colorectal cancer in Greenland

Secular trends in colon and rectal cancer relative survival

Impact of tumor location and variables associated with overall survival in patients with colorectal cancer: A mayo clinic colon and rectal cancer registry study

Prognostic analysis and comparison of colon cancer in Han and Hui patients

The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses

Conducting meta-analyses in R with the metafor

Impact of screening programme using the faecal immunochemical test on stage of colorectal cancer: Results from the IMPATTO study

Time to diagnosis and stage of symptomatic colorectal cancer determined by three different sources of information: A population based retrospective study

Time from first presentation in primary care to treatment of symptomatic colorectal cancer: Effect on disease stage and survival

Colorectal Cancer Screening and Prevention in the COVID-19 Era

Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period

In particular, we consider three macro-regions (North, Centre and South-Islands) and the 50-69 age class which is the target population of the screening program

there are differences in the Italian macro-regions in covering the target population (i.e. sending invitations for screening), with a 95% coverage in the North, 90% in the Centre and 45% in the South-Islands. Given these percentages, we estimate a total of 6439047 sent invitations. The last report of the National Screening Observatory (ONS

 Figure S1 . Flowchart for the "stage-delay" meta-analysis. Records Full-text articles excluded (n=9) with reasons: -no delay data; -no stage percentages*. * One study was excluded because it provides the percentages by stage only in graphical form. A data request to the authors was made by email, but no reply was obtained.

(meta-analysis) (n = 8)Records identified through database searching SCOPUS (n = 343)